Warning letter
Delta Pharma, Inc.: warning letter of Sep 17, 2004
FDA warning letter UCM146601 · New Orleans District Office
Key facts
| Reference number | UCM146601 |
|---|---|
| Company | Delta Pharma, Inc. |
| Subject | New Drug/Adulterated/Misbranded |
| Issue date | Sep 17, 2004 |
| Posted date | Sep 17, 2004 |
| Issuing office | New Orleans District Office |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(3), 201.115, 211, 211.63, 211.180, 211.22(d), 211.42(c)(10)(iv), 211.67(b), 211.80(a), 211.80(d), 211.84(d)(2), 211.94(d) and 6 more |
| Country | 3 |
| Inspection city | Ripley |
| Inspection ZIP | 38663-1709 |
| Inspection start date | Mar 8, 2004 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: